The natural history of treated Parkinson's disease in an incident, community based cohort
- PMID: 21593513
- DOI: 10.1136/jnnp.2011.240366
The natural history of treated Parkinson's disease in an incident, community based cohort
Abstract
Background: Our understanding of the natural history of idiopathic Parkinson's disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unselected patients followed from the point of diagnosis.
Methods: A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn-Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demogr‘aphic, clinical and genetic variables was evaluated using survival analysis.
Results: Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn-Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.
Conclusions: Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.
Comment in
-
The natural history of treated PD in an incident, community-based cohort: does the future begin?J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1065. doi: 10.1136/jnnp.2011.246835. Epub 2011 Jul 5. J Neurol Neurosurg Psychiatry. 2011. PMID: 21730104 No abstract available.
Similar articles
-
Differential progression of motor impairment in levodopa-treated Parkinson's disease.Mov Disord. 2000 May;15(3):479-84. doi: 10.1002/1531-8257(200005)15:3<479::AID-MDS1009>3.0.CO;2-P. Mov Disord. 2000. PMID: 10830412
-
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64. doi: 10.1136/jnnp-2013-305277. Epub 2013 Jun 18. J Neurol Neurosurg Psychiatry. 2013. PMID: 23781007
-
Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?PLoS One. 2021 Dec 22;16(12):e0261302. doi: 10.1371/journal.pone.0261302. eCollection 2021. PLoS One. 2021. PMID: 34937068 Free PMC article.
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
-
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(11):145-51. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID: 25629138 Review. Russian.
Cited by
-
Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.Front Neurol. 2024 Sep 26;15:1452741. doi: 10.3389/fneur.2024.1452741. eCollection 2024. Front Neurol. 2024. PMID: 39391167 Free PMC article.
-
Multidimensional Assessment of Individuals with Parkinson's Disease: Development and Structure Validation of a Self-Assessment Questionnaire.Healthcare (Basel). 2022 Sep 21;10(10):1823. doi: 10.3390/healthcare10101823. Healthcare (Basel). 2022. PMID: 36292272 Free PMC article.
-
Gait impairment-related axonal degeneration in Parkinson's disease by neurite orientation dispersion and density imaging.NPJ Parkinsons Dis. 2024 Feb 27;10(1):45. doi: 10.1038/s41531-024-00654-w. NPJ Parkinsons Dis. 2024. PMID: 38413647 Free PMC article.
-
Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes.Degener Neurol Neuromuscul Dis. 2013 Jun 27;3:33-39. doi: 10.2147/DNND.S19807. eCollection 2013. Degener Neurol Neuromuscul Dis. 2013. PMID: 30890892 Free PMC article. Review.
-
Genome-wide determinants of mortality and motor progression in Parkinson's disease.NPJ Parkinsons Dis. 2024 Jun 7;10(1):113. doi: 10.1038/s41531-024-00729-8. NPJ Parkinsons Dis. 2024. PMID: 38849413 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical